+ Bookmark This Page  
Preferences  |  10:48 PM
  1. Home
  2. Latest News
  3. Submit Press Release
  4. Search Jobs
  5. Search Businesses
  1. News Home
  2. News Archive
  3. By Category
  4. By Location
  5. By Date
  6. By Tag
  7. Newsletter
  8. 40,000 RSS Feeds
  9. Submit Free Press Release
 
Filter News
Category

Country

State / Province
Select Country First

City / Town
Select State First

Repromedix Appoints Dr. Michael J. Burns Chief Executive Officer

National reproductive diagnostic laboratory positions for continued growth
 

 
Repromedix Logo

Repromedix Logo

FOR IMMEDIATE RELEASE

PRLog (Press Release)Jul 17, 2007 – FOR IMMEDIATE RELEASE

Contact:  Lisa Scimemi
Phone: 781-404-1752
Email: lscimemi@repromedix.com



Repromedix Appoints Dr. Michael J. Burns Chief Executive Officer
National reproductive diagnostic laboratory positions for continued growth

Woburn, MA, July 17, 2007 –Repromedix Corp., the leading national diagnostic laboratory for advanced reproductive testing, announced today that Dr. Michael J. Burns has been appointed Chief Executive Officer.

“We are delighted that we were able to attract Dr. Burns to Repromedix,” said Jack Davis, Chairman of the Board.  With over 25-years experience growing international pharmaceutical and healthcare companies, Dr. Burns brings extensive senior and general management experience in the critical areas of medical research and development, corporate and business development,  product licensing and sales force delivery and marketing.”

Dr. Burns comes to Repromedix after having served more than ten years as the President and Chief Operating Officer of Ferndale Laboratories, a leader in the manufacturing and marketing of pharmaceutical products and medical devices.  Having joined Ferndale in 1992, Dr. Burns also served as the President of the company’s Pharmaceutical Division and Vice President of Corporate Development.  Prior to Ferndale, Dr. Burns held senior management and leadership positions with Yamanouchi Europe B.V., Smith, Kline & French Pharmaceuticals Ltd., and Napp Laboratories Ltd.

“The increasing number of women seeking to have children later in life has significantly contributed to the development of sophisticated and innovative diagnostic techniques in reproductive medicine,” said Paul Kowalski, President and Vice President of Sales. “Repromedix has grown from a pioneer to national leader in infertility diagnostics.  We look forward to leveraging Dr. Burns’ industry experience and expertise as we continue to meet the growing need for valuable medical and genetic information that can contribute to the attainment of parenthood for so many.”

“I couldn’t be more excited to join the incredible team of infertility professionals at Repromedix,” said Dr. Michael J. Burns. “I am especially attracted to Repromedix’ decade-long passion for helping doctors help couples start families.  I share deeply the company’s entrepreneurial spirit, its commitment to excellence and its vision for future growth and medical partnership opportunities.  I look forward to contributing to the company’s continued growth and success.”

A British native, Dr. Burns holds a postgraduate degree in Pharmacology from the University of Nottingham and an undergraduate degree from the University of Reading in Physiology, Biochemistry and Chemistry.

About Repromedix (www.repromedix.com)

Repromedix is the leading national diagnostic laboratory for advanced reproductive testing.  By taking an interdisciplinary approach to clinical infertility testing that encompasses endocrinology, immunology and genetics, Repromedix offers the most comprehensive suite of advanced diagnostic tests that provide valuable information regarding complex problems of reproductive failure.  Since its inception in 1995, the company has assisted more than 45,000 patients by conducting over 100,000 diagnostic tests for recurrent pregnancy loss, premature ovarian failure, male infertility and unexplained infertility.  


###

# # #

Repromedix is the leading national diagnostic laboratory for advanced reproductive testing. Repromedix offers the most comprehensive suite of advanced diagnostic tests that provide valuable information regarding complex problems of reproductive failure. Since its inception in 1995, the company has assisted more than 45,000 patients by conducting over 100,000 diagnostic tests for recurrent pregnancy loss, premature ovarian failure, male infertility and unexplained infertility.

# # # + Share This Article Click to see PDF Version of this Press Release

Email to a Friend   Email to Author       Previous News   Next News


Issued By:Repromedix
Website:http://www.repromedix.com
Email:Click to contact author
Phone:781-404-1752
Fax:781-935-3068
Address:86-88 Cummings Park, Woburn
State/Province:Massachusetts
Zip:01801
Country:United States
Categories:Biotech, Health, Medical
Tags:Diagnostic Tests, Recurrent Pregnancy Loss, Premature Ovarian Failure, Male Infertility, Nexplained Infertility

Disclaimer:   Issuers of the press releases are solely responsible for the content of their press releases. PRLog.Org can't be held liable for the contents of the press releases.   Report Abuse


Related

Mom of Two Children Who Have Autism Launches Blog to Help Other Families Coping with Autism

TCEB sponsors The World Medical Health Tourism Conference in Phuket, Thailand

Sneha Diagnostics Plans to Open 10 State of the Art Medical Diagnostics Centers Across AP, India

Herbal Infusions Tea Co. Announces An Addition To Their Signature Line of Tea

New Organization Filling Growing Need For Specialized Fertility Treatment Support


Most Viewed (Last 7 days)

LifeCaps to Visit Houston After Hurricane Ike to Promote Survival Kits - 1523 views

Homemade Halloween Decorations Create Halloween Fun - 1294 views

New Music Awards, Announcing The Swi Awards - 874 views

About Designeroutletboutique.com & Additional Discount Coupon Codes - 799 views

The Truth About GPS Technology - 762 views



Previous News

Next News

Are you a Journalist?


For Businesses ...


Tutorial on Free Marketing




  1. SiteMap
  2. Contact PRLog
  3. Privacy Policy
  4. Terms of Use
  5. Copyright Notice